Nektar Therapeutics (NKTR) Competitors & Peers

The 5 largest companies in the same industry as Nektar Therapeutics, by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.

How we identify peers ↗

Ticker	Relationship	Price	Comparables
VRTX	Peer	$508.34	P/E 30.0RSI 41Cap 128.8 B
REGN	Peer	$784.85	P/E 19.5RSI 48Cap 80.8 B
ARGX	Peer	$990.32	P/E 38.0RSI 53Cap 62.1 B
RVMD	Peer	$190.95	RSI 41Cap 40.9 B
CSLLY	Peer	$31.12	P/E 18.2RSI 71Cap 60.1 B

How these relationships were derived

Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.

Confirmed relationships (cited)

Sourced from a public filing or disclosure — each links to its origin.

PFESupplier
Own 10-K customer-concentration disclosure: Pfizer = 12% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗
TKPHFSupplier
Own 10-K customer-concentration disclosure: BaxaltaIncorporatedOrTakedaPLC = 18% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗
BAYN.DESupplier
Own 10-K customer-concentration disclosure: Bayer = 10% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗
AZNSupplier
Own 10-K customer-concentration disclosure: AstraZeneca = 29% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗
LLYSupplier
Own 10-K customer-concentration disclosure: EliLillyAndCompany = 42% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗

Model-inferred relationships (unverified)

Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.

LLYPartner
Nektar partners with Eli Lilly on PEGylated immunology drug pipelines.
Model-inferred, unverified — treat as a lead, not evidence
BMYPartner
Nektar co-develops oncology candidate drug therapies with BMS.
Model-inferred, unverified — treat as a lead, not evidence